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review and meta-analysis of clinical studies
Pragya Shresthaa,b*, Paras Karmacharyac, Zhen Wangd, Anthony Donatob and Avni Y. Joshie
ABSTRACT
Background: Monthly intravenous immunoglobulin (IVIG) and weekly subcutaneous immuno-
globulin (SCIG) have been regarded as therapeutically equivalent treatments for primary immu-
nodeﬁciency diseases (PIDD). Immunoglobulin G (IgG) trough level is used as a monitoring
measure for infection prevention.
Objective: A systematic review and meta-analysis were performed to elucidate the relationship
between IgG dosing, trough IgG levels with overall infection incidence in patients with PIDD
receiving IVIG and SCIG therapy.
Methods: Medline, EMBASE, Cochrane, Central, and Scopus were searched for studies published
from Jan 2010–June 2018, fulﬁlling the inclusion criteria. DerSimonian and Laird random-effects
method were used to pool the difference of IgG trough levels. Random-effect meta-regression
was used to evaluate infection incidence per 100 mg/dl IgG trough increase though IVIG and
SCIG.
Results: Out of 24 observational studies included, 11 compared IgG trough levels among SCIG
and IVIG (mean difference: 73.4 mg/dl, 95% CI: 31.67–119.19 mg/dl, I2 ¼ 45%, p ¼ 0.05), favoring
weekly SCIG. For every 100 mg/dl increase in the trough, a linear trend of decreased incidence
rates of infection was identiﬁed in SCIG patients (p ¼ 0.03), but no similar trend was identiﬁed in
trough levels vs. infection rates for patients receiving IVIG (p ¼ 0.67).
Conclusion: In our study, weekly SCIG attained a higher trough level in comparison to monthly
IVIG. Higher SCIG troughs were associated with lower infection rates, while IVIG troughs
demonstrated no relationship.
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INTRODUCTION
Immunoglobulin G (IgG) replacement therapy is
the mainstay of treatment in many primary immu-
nodeﬁciency diseases (PIDD) associated with hu-
moral immune defects, including common variable
immunodeﬁciency disease (CVID), congenital hy-
pogammaglobulinemia and agammaglobulin-
emia.1 While intravenous immunoglobulin (IVIG)
was the most common mode of replacement in
1980–1990, subcutaneous IgG (SCIG)
administration has become increasingly common
in clinical practice since the 1990s.2 Both IVIG
and SCIG have been regarded therapeutically
equivalent (have same efﬁcacy for prevention of
bacterial infections) in patients with PIDD3,4 and
choice of the use of IVIG vs. SCIG has to take
into account the comparative advantages and
disadvantages between these for a given patient.
For example, advantages of SCIG being fewer
systemic adverse events,4,5 improved quality of
life5,6 and stable IgG levels6,7 and disadvantages
being more local infusion sites reactions
accounting for adverse events8–11 and
requirement of frequent infusions (weekly vs.
monthly).4,5
It is unclear if there are universally accepted
threshold IgG levels that correlate with adequate
protection from severe infections. Serum IgG con-
centrations500 mg/dl following IgG therapy have
been recommended for adequate protection from
serious infections in PIDDs.12–14 The serum IgG
trough level, deﬁned as concentration preceding
the next dose of immunoglobulin (Ig) infusion,
has been regarded as an important guide to
therapy.15 Several recent studies have shown
higher serum IgG concentrations, resulting from
higher intravenous IgG and subcutaneous IgG
dosing regimens, associated with infection
prevention and decreasing infection-associated
morbidity.13,16,17 Data from earlier studies have
endorsed IgG trough level of 500 mg/dl as an
appropriate initial minimum target for infection
prevention in PIDD.14,18 However, subsequent
clinical evidence has prompted recommendations
for higher target levels of >800 mg/dl19 and 650–
1000 mg/dl20 in recent clinical guidelines. Due to
inconsistent trough levels, a recommendation to
individualize treatment plans based on symptoms
and infections has been proposed.3 Studies have
also suggested no signiﬁcant differences in
efﬁcacy or adverse reaction rates between
subcutaneous and intravenous immunoglobulin
treatment.4
In this systematic review and meta-analysis, we
sought to compare IVIG vs. SCIG in PIDD patients
and its effects on IgG trough levels, the overall
incidence of infection and serious infections
(including pneumonia) to help guide clinicians in
appropriate clinical decision making.
METHODS
The preferred reporting items for systematic re-
views and meta-analyses (PRISMA) statement as
recommended by the Cochrane Collaboration for
reporting systematic reviews21 was used (Fig. 1).
This systematic review included studies published
from Jan 1, 2010, to May 30, 2018. A meta-
analysis on studies earlier than 2010 was already
carried out by Orange et al.;13 we focused our
review on studies after 2010 to cover newer
studies since the recent advancements in the
treatment of these diseases. Searches of
MEDLINE, EMBASE, Cochrane Library, and
Scopus databases were carried out to identify
eligible studies. A combination of subject
headings (MeSH, EMTREE) and text words was
used for each concept. Search terms and
synonyms for "immunologic deﬁciency" and
"immunoglobulins" were combined in the search
with "AND" using Boolean logic. Synonyms for
immune deﬁciency included "immunologic
deﬁciency syndromes", "common variable
immunodeﬁciency", "dysgammaglobulinemia",
"agammaglobulinemia",
"hypogammaglobulinemia" (the text words
allowed for both American and British spellings).
Synonyms for immunoglobulins included
"immunoglobulins", “intravenous”, “subcutaneous”
abbreviations of IVIG, SQIG, as well as speciﬁc
brand names such as Carimune, Gammagard, and
subject headings which included speciﬁc routes of
injection such as immunoglobulins/intravenous or
immunoglobulins/subcutaneous were included.
The eligibility criteria for this systematic review
were (1) human subjects with a diagnosis of PIDD
undergoing IgG treatment; (2) reported outcomes
comparing IVIG, SCIG, or different dosage/forms
of IVIG/SCIG; (3) Documented IgG trough level; (4)
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Studies showing an outcome of interest (overall
infection, pneumonia/serious infection, or hospi-
talization rates). Studies without documented
therapy studies not reporting any outcome of in-
terest or deﬁnitions of those outcomes, and
studies without a comparator were excluded from
our analysis. Conference extracts were excluded.
The language was restricted to English.
Study abstracts were screened by two in-
vestigators (PS and AJ), full-text articles were
reviewed for those that fulﬁlled eligibility criteria
and irrelevant articles were excluded. Disputes
were settled with mutual agreement. To minimize
data duplication as a result of multiple reporting,
we compared articles from the same investigator.
Relevant data were extracted by two investigators
(PS and AJ) and checked by another (PK).
From each study, we extracted and tabulated
details on the study source, design, patient with
PIDD, type of PIDD included, mean age in years,
percentage of female patients, percentage of CVID
patients, the region of study, the total population
of study and duration of the study (Table 1).
Furthermore, we extracted the details on
treatment, including the type of treatment IgG
used, comparison group, dosing protocol, IgG
trough level, pneumonia rate, overall infection
rate, days of hospitalizations, days missed from
school/work and adverse events per patient-year
(Table 2).
Study quality was formally evaluated by two in-
vestigators (PS and AD) using a modiﬁed
Newcastle-Ottawa Quality Assessment Scale22 for
observational studies. Any discrepancies were
resolved by a third author (PK) (Supplementary
File 1).
The outcomes from individual studies were
calculated with RevMan, version 5.3 (Cochrane
Collaboration, Oxford, United Kingdom). The
Inverse-Variance method was used to compare the
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Fig. 1 Flow chart describing systematic research and study selection process
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SN Studies Study design Region
Total
Population
of Study
Study
duration
Treatment
IgG used
(Brand
name)
Comparison
No. of
patients
(n)
Mean age in
years (SD/
range)
Female
gender (n,
%)
1 Aydiner
201529
Prospective,
observational
Turkey 16 10 months SCIG 5–10% IVIG vs.
SCIG
16 7.5 (0–33 years) 7 (43.7%)
2 Berger
201030
Open-label,
uncontrolled trial
Germany 51 (adults ¼ 42,
children ¼ 9), (3–
66 years)
12 months 16% SCIG
(Vivaglobin)
Historic IVIG vs. 51 37.8  19.40 30 (58.8%)
16% SCIG 31 10.4  20.24 18 (58.1%)
3 Ballow
201631
Phase IV, multi-
center, open-
label study
USA 24 (2–16 years) 12 months 5% DIF IVIG
(Flebogamma)
Historic IVIG vs.
5% DIF IVIG
24 9.0 (2.0–16.0) 5 (20.8%)
4 Bezrodnik
20138
Observational,
prospective/
retrospective,
open-label
multicenter study
Argentina 15 (6–18 years) 36 weeks 16% SCIG
(Beriglobina P)
16% SCIG 15 10.6 (3.7) 4 (27%)
5 Bezrodnik
201432
Observational,
descriptive and
ambispective
study
Argentina 32 (8 months - 40
years)
36 weeks 16% SCIG
(Beriglobina P)
Historic IVIG vs.
SCIG (15 via
pump and 2 via
push)
32 11 (8–40) 15 (46.9%)
6 Borte
20179
Prospective, non-
controlled
clinical trial
Europe 49 (>2 years) 52 weeks IVIG 10%
(Kiovig)/SCIG
16% (Subcuvia)
IVIG 10%/SCIG
16% (period1) vs.
33 (IVIG), 16
(SCIG16%)
17 (2–67) 19 (38.8%)
SCIG 20% SCIG 20%
(period2)
49 (SCIG
20%)
7 Borte
201710
Prospective,
open-label, non-
controlled, non-
randomized,
multicenter,
phase 3 study
USA and
Europe
51 (13 children,
12 adolescents,
26 adults)
12 months IVIG 10%
(Panzyga)
3-weekly IVIG
then IVIG 10%
21 26.2  21.2 14 (66.7%)
4-weekly IVIG
then IVIG 10%
30 27.2  18.2 19 (63.3%)
8 Borte
201133
Prospective,
open-label,
multicenter,
single-arm,
phase III
Europe 18 (2–11 years)
and 5 (12–15
years) and 28
(16–64 years)
12 weeks (wash-
in/wash-out
period)þ28
weeks efﬁcacy
period
SCIG 20%
(Hizentra)
IVIG vs. 20%SCIG 51 7.2  2.5
(children),
14  1
(adolescents),
34.1  12.7
(adults)
5 (27.8%)
children,
0 adolescents,
11 (39.3%)
adults
9 Haddad
20126
Comparative
study for Open-
label, multi-
USA and
Europe
EU ¼ 46 12 weeks wash-in/
wash-out
period þ efﬁcacy
SCIG 20%
(Hizentra)
SCIG 20% same
dose as historic
IVIG
46 21.5  15.6 15 (33%)
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center, single-
arm design
period (28 weeks
in Europe and 52
weeks in USA)
USA ¼ 38 SCIG 20% 1.5 x
dose as historic
IVIG
38 36.3  19.5 21 (55%)
10 Hagan
201011
Prospective,
open-label,
multicenter,
single-arm,
phase III
USA 49 (5–72 years) 12 weeks wash-in/
wash-out period
and 12-month
efﬁcacy period
SCIG 20%
(IgPro20)
IVIG then SCIG
20%
49 36.3  19.52 21 (55.3%)
11 Jolles
201134
Prospective,
open-label,
multicenter,
single-arm,
phase III
Europe 53 (17 < 12
years, 5 < 16
years,31  16
years).
12-week wash-in/
wash-out period,
28 weeks efﬁcacy
period
SCIG 20%
(Hizentra)
Switch from IVIG
to SCIG 20%
46 (ITT), 23
(PPK)
21.5  15.6 15 (32.6%)
12 Kanegane
201435
Prospective,
multicenter,
open-label,
single-arm,
phase III
Japan 25 (2–12
years ¼ 11, 12–
16 years ¼ 8, 16–
65 years ¼ 26),
12-week wash-in/
wash-out period
with 12-week
efﬁcacy period
IgPro20 SCIG
(Hizentra)
Switch from IVIG
to SCIG 20%
24 (ITT), 21
(PPK)
17.5 (3–58) ITT,
19(3–58) PPK
9 (37.5%) ITT, 7
(33.3%) PPK
13 Krivan
201636
Open-label,
prospective,
multicenter,
single-arm study
Europe 62 (2–61 years),
36 adults and 26
pediatrics
12 months IVIG (IqYmune) Switch from IVIG
to IqYmune
62 27.4 (2–61) 19 (30.6%)
14 Melamed
201637
Open-label,
multi-center,
non-randomized
phase 4 study
USA(7),
Chile(1),
Israel (1)
25 (3–16 years) 12 months 5% IVIG
(Gammaplex)
Switch from IVIG
to IVIG 5%
14 on 21-day
infusion and
11 on 28-day
infusion
10.4  3.84 6 (24%)
15 Moy 201038 Prospective,
open-label,
multi-center,
non-
comparative
USA 50 (3 years) 12 months 5% IVIG with and
5 g d-sorbitol
(Gammaplex 5%)
Switch from IVIG
to 5% IVIG
22 on 21-day
and 28 on
28-day
infusion
schedule
44  19.10 24 (48%)
16 Patel
201539
Retrospective
chart review
USA 88 (0-<2
years ¼ 34, 2–5
years ¼ 54)
45.5 months SCIG 20%
(Hizentra)
Historic Hizentra
use
88 34 months (2-
59)
35 (40%)
17 Quinti
201117
Prospective,
multi-center
Italy 302
(CVID þ XLA)
3.8 years (CVID)
5.8 years (XLA)
IVIG IVIG in CVID vs.
XLA
302 28.7  18.4 (3–
68 years) (CVID)
NA
4.9  6.2 (16
days-40.9 years)
(XLA)
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SN Studies Study design Region
Total
Population
of Study
Study
duration
Treatment
IgG used
(Brand
name)
Comparison
No. of
patients
(n)
Mean age in
years (SD/
range)
Female
gender (n,
%)
18 Stein
201640
Prospective,
open-label,
single-arm,
multicenter,
historically
controlled, phase
III
USA and
Canada
40 (2–70 years)-
39 in US and 6 in
Canada
12 months 10% IVIG
(Kedrion)
Historic Hizentra
use (mean age of
initiation of
Hizentra 34
months)
88 34 months (2-
59)
35 (40%)
19 Suez
201641
Prospective,
open-label
clinical trial
USA and
Canada
74 (2 years) 52 weeks IVIG 10% and
SCIG 20%
74 39.9  20.7 13 (29%)
20 Viallard
201742
Prospective,
multicenter, non-
randomized,
open-label
France 22 (18–70 years) 9 months 5% lyophilized
IVIG (Tegeline)
and IV Ig new
generation
(ClairYg IGNG)
Period 1-IVIG
10% then SCIG
205 in period 2, 3
and 4
22 36 (3–83) 37 (48.1%)
21 Vultaggio
201543
Prospective,
observational,
multicenter
Italy 50 (group A >14
years ¼ 43,
Group B  14
years ¼ 7)
24 months SCIG 16%
(Vivaglobin)
IVIG/SCIG vs.
SCIG 16%
50 41.9  12.2 8 (36.4%)
22 Wasserman
201244
Open-label,
phase III, efﬁcacy
and pharma-
cokinetic study
USA 63 (6–11
years ¼ 4, 12–17
years ¼ 6, 18–64
years ¼ 44, >65
years ¼ 9)
12 months IVIG 10%
(Biotest)
IVIG vs. SCIG
16%
50 31.7  15.7 19 (38%)
23 Wasserman
201245
Prospective,
multicenter,
open label,
phase III
USA and
Canada
87 (2–12
years ¼ 14, 12
years ¼ 73)
14–18 months SCIG/IVIG
preceded by
rHyPH20
[recombinant
human
hyaluronidase
(IGHy)]
IVIG 10% infusion
in 21 day vs. 28
day
87 41.2  19.68 32 (50.8%)
24 Wasserman
20167
Prospective,
open-label, non-
controlled, multi-
center studies,
phase III trial
[Extension of
earlier study
(2012)]
USA and
Canada
63 (<18
years ¼ 15, 18
years ¼ 48)
30 months SCIG preceded
by rHyPH20
[recombinant
human
hyaluronidase
(IGHy)]
SCIG/
IVIG þ rHyPH20
vs. IVIG/SCIG
alone
87 35 (4–78) 43 (49.4%)
Table 1. (Continued) Baseline Characteristics of clinical studies included in systematic review and meta-analysis. Legend: IgG- Immunoglobulin, n ¼ number, SD- Standard Deviation, IVIG-
Intravenous Immunoglobulin, SCIG- Subcutaneous Immunoglobulin, NA-not available, EU ¼ Europe, USA¼ United States of America, ITT- Intent to treat, PPK- per-protocol pharmacokinetic, CVID¼ Common
variable immunodeﬁciency disease, XLA ¼ X-linked agammaglobulinemia
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SN. Studies Type ofIgG used
Dosing protocol,
Mean(range) mg/
Kg/week
IgG trough level
(Mean  SD) mg/
dl
Severe
infections
n (rate/
patient/
year)
Overall
infection (n,
CI)-annual
rate per
patient
Days of
hospitalization
(n, Mean  SD)
Days missed
from work/
school (n,
Mean  SD)
Adverse
events/
patient/
year
1 Aydiner
201529
IVIG 330–1250 mg/kg/wk 976  564 mg/dl 0 7 events in 4 pts
in 10 months
na na na
SCIG 300–430 mg/kg/wk 1025  409 mg/dl
2 Berger
201030
IVIG 100–200 mg/kg/wk 914.8  273.37 mg/dl 0.03 3.42 na 4.5/subject/year 27.5
16% SCIG 878  234.77 mg/dl
3 Ballow
201631
IVIG 300–800 mg/kg/wk 800–1000 mg/dl 1 episode 0.051 0.2  1.1 6.2  17.7 20.2
5% IVIG
4 Bezrodnik
20138
IVIG 556 mg/kg/month
(420–870)
960.2 mg/dl 3 episodes in
IVIG/1 in
SCIG
1.4 0 na na
16% SCIG 139 mg/kg/wk (105–
181)
1317 mg/dl (wk16),
1309.2 mg/dl (wk 24)
and 1231.5 mg/dl (wk
36)
0.4 0 na 0.14
5 Bezrodnik
201432
IVIG (48
weeks)
na 1005.33  419.420 mg/
dl
4 episodes 2–7 na na 0.13
16% SCIG (9
months)
133 mg/kg/wk (100–
192)
1205  457.990 mg/dl 3 episodes 1–2 na na 0.02
6 Borte 20179 Period 1-IVIG
10% for
13 wk/SCIG
16% for
12 wks.
125  42 mg/kg/week
(20% SCIG)
IVIG 10% ¼ 720 mg/dl
SCIG 16% ¼ 897 mg/dl
0 IVIG,
1(0.27) SCIG
16%)
6.29 rate (IVIG),
8.92 rate (SCIG
16%), 4.38 (SCIG
20%)
1 (0.12) IVIG,2 (0.54)
SCIG 16%
90 (10.69) IVIG/
187(50.42) SCIG
0.058
Period 2-
SCIG 20% for
52 wk
SCIG 20% ¼ 827 mg/dl 1(0.022) 200(4.38) 7(0.15)-SCIG 710 (15.55)
7 Borte
201710
10% IVIG (/3
weeks)
485 mg/kg/month 1100–1220 mg/dl 3.68 (overall)
4.19 (3 weekly))
na 37 absences
(61.95%)
Serious AE
13% (4 weekly)
vs. 5% in 4
weekly
10% IVIG (/4
weeks)
810–870 mg/dl 3.33 (4 weekly) 1 (0.08) 3.64
(continued)
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SN. Studies Type ofIgG used
Dosing protocol,
Mean(range) mg/
Kg/week
IgG trough level
(Mean  SD) mg/
dl
Severe
infections
n (rate/
patient/
year)
Overall
infection (n,
CI)-annual
rate per
patient
Days of
hospitalization
(n, Mean  SD)
Days missed
from work/
school (n,
Mean  SD)
Adverse
events/
patient/
year
8 Borte
201133
IVIG/SCIG 200–800 mg/kg/wk 694 mg/dl (c), 790 mg/
dl (a), 781 mg/dl (ad) g/l
0 4.77/5.18 (a)/
5.47 (ad)
8.36(c),0(a),0.63(ad) 1.7 (c), na (a), na
(ad)
0.04(c),0.035
(a),0.08(ad)/
infusion
20% SCIG 129.9 mg/kg/wk
-children(c),
113.7 mg/kg/wk-
adolescents (a) and
114.3 mg/kg/wk- adults
(ad)
786 mg/dl (c), 791 mg/
dl (a), 831 mg/dl (ad)
0
9 Haddad
20126
20% SCIG
(1:1) EU
120 mg/kg/wk 810  144 mg/dl 0 5.18 3.48 8 0.59 events/
infusion (1:1)
20% SCIG
(1.5:1) USA
210 mg/kg/wk 1254  322 mg/dl 0 2.76 0.2 2.06 0.06 in 1:1
10 Hagan
201011
20% SCIG 179.6–224.3 mg/kg
(IgPro20)
1210–1290 mg/dl 0 2.76 0.2 2.06 local
AE ¼ 0.592,
other than
local
AE ¼ 0.043
11 Jolles
201134
IVIG Pre study ¼ 702 mg/dl 1(wash
out) ¼ 0.03
events/
patient/year
5.18 3.48 8 0.177/infusion
20% SCIG 120  35.72 mg/kg/wk
(20% SCIG)
On infusion ¼ 809 mg/
dl
12 Kanegane
201435
IVIG 77.3  30.5 mg/kg/
month
653  140 mg/dl (IVIG) 0 2.98 0.55 3.48 0.461/infusion
20% SCIG 87.8  35.2 mg/kg/wk
SCIG
715  151 mg/dl (SCIG)
13 Krivan
201636
IqYmune 220–970 mg/kg 579  203 mg/dl 1 (0.017) 3.79 0.89 1.01 0.45/infusion
773/- 236 mg/dk (IVIG)
14 Melamed
201637
IVIG 5% 21-
day infusion
300–800 mg/kg/wk 21-day infusion ¼ 987–
1083 mg/dl
2 (0.09) 3.08 3.5 1.1 0.39/infusion
IVIG 5% 28-
day infusion
28-day infusion ¼ 822–
882 mg/dl
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15 Moy 201038 IVIG 5% 469.4 mg/kg/month
(21-day infusion)
466.2 mg/kg/month (28-
day infusion)
21-day infusion ¼ 936–
1240 mg/dl
0 3.07 2 days 8.73 1 AE/3
infusions
28-day infusion ¼ 833–
1140 mg/dl
16 Patel
201539
SCIG 20% 674 mg/kg/wk (260–
2000)
552 mg/kg/month (IVIG)
794 mg/dl (on IVIG) and
943 mg/dl (IGSC 20%)
0.03 0.067 rate na na 41 (47%) local
AEs
17 Quinti
201117
IVIG CVID- 398  167 mg/
kg/wk
CVID-667  176 mg/dl 0.06–0.1
episodes
patient-year
na na na na
XLA-608  273 mg/kg/
wk
XLA-758  202 mg/dl 0.03–0.11
episodes
patient-year
18 Stein
201640
10% IVIG 501.7 mg/kg/month 923.9 mg/dl 2 (0.04) 2.9 0.6 2.8 44(98%)- 450
events
19 Suez
201641
IVIG 10% and
SCIG 20%
222  71 mg/kg/wk 1523 mg/dl with IGSC
and 1200 mg/dl in IVIG
10% in 3 weeks
0 3.86 in IVIG 0.02 1.16 0.036/infusion
2.41 in SCIG
20 Viallard
201742
Tegeline 442 mg/kg/month
(286–608)
Tegeline 805  134 mg/
dl
Tegeline-0 Tegeline-4.35 (0–
21.8)
Tegeline-0 Tegeline-8.8
(6.4–11.9)
Tegeline-0.09
ClairYg ClairYg 917  172 mg/
dl
ClairYg-0 ClairYg-4.3(0–
15.1)
ClairYg-0 ClairYg-0.3(0.1–
0.9)
ClairYg-0.08
21 Vultaggio
201543
IVIG Maintenance of total
monthly dose of
historic IVIG split into
four weekly doses of
SCIG
Baseline
635  242.8 mg/dl
5 (0.056) 33/39 patients
(84.6%)-
infection
1.93  4.08 (IVIG) 15.27  23.17
(IVIG)
Local reactions
(14/50 ¼ 28%)
SCIG 16% 671  217.5 mg/dl 0.64  2.94 (SCIG) 2.26  4.45
(SCIG)
22 Wasserman
201244
IVIG 10% 500 mg/kg/wk (254–
1029)
1076  254 mg/dl (606–
1780 mg/dl) in 21-days
2 (0.035) 2.6 (2.3–2.7) 0.21 2.28 937 events
943  215 mg/dl (487–
2250) in 28-days
(continued)
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IVIG and SCIG trough levels. Risk Ratios (RRs) and
95% conﬁdence intervals (CIs) were estimated us-
ing a random-effects method to control the het-
erogeneity as their assumption accounts for the
presence of variability among the studies.23 The I2
statistic was used to estimate the percentage of
heterogeneity among the studies. I2
values < 30% were considered a low
heterogeneity, 30%–60% as moderate, and >60%
as high.24 Peto odds ratio was used when the
event rate was <1%. DerSimonian and Laird
random-effects method was used to pool the dif-
ference of IgG trough levels along with random-
effect meta-regression to evaluate infection inci-
dence per 100 mg/dl IgG trough increase through
IVIG and SCIG. A p-value of <0.05 was used as a
level of signiﬁcance. Publication bias was assessed
by visual assessment of funnel plots (Supplemen-
tary File 2).
RESULTS
Our study included 24 studies that met our
eligibility criteria, of which 21 were prospective, 2
were ambispective and 1 was a retrospective study
(Table 1). Twelve studies were conducted in the
United States, 10 in European countries (2 with
the US), 4 in Canada (with the US), 2 in
Argentina, 1 in Japan and Turkey each, and a
multinational study by the US along with Chile
and Israel. Treatment IgG products used and
study durations were included. The mean patient
age was 23.8 years in 24 studies, with 10 studies
including those <18 years and 14 including
those >18 years of age. Seven studies had more
than 50% females, but males comprised the
majority of the patient population overall.
Disease types resulting in PIDD by the study are
shown in Supplemental Table 2. CVID was the
predominant PIDD with 5 studies showing >80%
of CVID in the affected patient population,
followed by XLA.
IVIG had been used in all the studies as a his-
torical form of IgG administration and was
compared with SCIG in 15 studies. IVIG adminis-
tration frequency was every 3 or 4 weeks, whereas,
SCIG dose was given weekly. Trough levels calcu-
lated in studies varied in terms of timing, with most
of the levels drawn prior to the next IVIG and SCIG
infusion. After reviewing the quality of studies, 11S
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studies were compared in the meta-analysis for
trough levels as depicted in the forest plot (Fig. 2).
Inclusion criteria of the studies stipulated
documented diagnosis of PIDD requiring IgG
therapy with a stable dose and trough level.
However, in one study done by Borte et al.,
patients above 2 years of age with PIDD
requiring 0.3–1 g/kg IgG for  3 months with
serum IgG trough 5 g/l only were included.
Patients with chronic infections with Hepatitis B,
C or HIV, on antibiotics, abnormal liver and renal
function tests, severe neutropenia, thrombotic
episodes, malignancy, currently receiving
immunosuppression, pregnant or nursing were
excluded in most studies. Reported details on
criteria for pneumonia diagnosis during the
course of treatment with IVIG and SCIG therapy
were limited, with some studies reporting the
diagnosis based on history, chest X-ray, physical
exam and need for hospitalization. Pneumonia
was also sometimes reported as a "serious
infection" separating it from the overall infections
diagnosed during the treatment period. However,
due to the low number of pneumonia diagnoses
reported in the studies, regression analysis was
focused on overall infections and serious
infections. The annual rate of infection per patient
was calculated, when not provided, for statistical
analysis. Days of hospitalization, days missed
from school and work, adverse events from the
IVIG and SCIG therapy were reviewed and
included if reported (Table 2).
Among the total 24 studies, 13 with IVIG therapy
and 11 with SCIG therapy were reviewed owing to
the availability of data required for comparative
study and meta-analysis. Eleven studies which
compared IVIG and SCIG therapy were included in
the initial meta-analysis. Higher mean trough level
attainment was evident in the SCIG group as
compared to IVIG with a mean difference of 75.43
(CI 31.67–119.19), with moderate heterogeneity
(I2 ¼ 45%) (Fig. 2).
Among 6 studies comparing IVIG vs. SCIG in
terms of the incidence of infection, the difference
in risk of overall infections (Risk difference ¼ 1.58,
95% CI: 0.75–3.33, p ¼ 0.23, I2 ¼ 96%) or serious
infections was not statistically signiﬁcant (Peto
odds ratio ¼ 1.94, 95% CI: 0.59–6.32, (p ¼ 0.59,
I ¼ 0%), but a clinically relevant difference could
not be ruled out (Fig. 3a and b).
Random-effects meta-regression analysis was
used to analyze the increase in IgG trough level
with a concomitant increase in IVIG and SCIG
dose. No notable linear relationship with dose-
dependent trough level was seen with either IVIG
or SCIG therapy (Fig. 4a and b). However, across
the studies included for regression analysis of
IVIG and SCIG trough vs. infection incidence
(Fig. 5a and b), each additional 100 mg/dl
trough attained through SCIG was associated
with a reduction in pneumonia incidence rate, as
displayed in Fig. 5b. No signiﬁcant trend was
apparent within the IVIG trough range as
depicted in Fig. 5a.
DISCUSSION
Our study shows higher IgG trough levels in
patients on SCIG vs. IVIG therapy. Among the 11
Fig. 2 Trough levels in SCIG vs. IVIG
Volume 12, No. 10, October 2019 11
Fig. 3 (a) and (b). Infection rates and serious infection rates in IVIG vs. SCIG
Fig. 4 (a) and (b). Effect of IVIG dose (mg/kg) on trough IgG level (mg/dl) and effect of SCIG dose (mg/kg) on trough IgG level (mg/dl). Each
data point corresponds to a single observation period in a patient group of an included study. Abbreviations, C, 95% conﬁdence interval;
IVIG, intravenous immunoglobulin; SCIG, subcutaneous immunoglobulin
Fig. 5 (a) and (b). Effect of IgG trough level (mg/dl) on infection incidence per patient-year in SCIG and IVIG groups. Each data point
corresponds to a single observation period in a patient group of an included study. Abbreviations, C, 95% conﬁdence interval; IVIG,
intravenous immunoglobulin; SCIG, subcutaneous immunoglobulin
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studies included in our meta-analysis of IVIG vs.
SCIG trough level, consistently higher trough
levels were observed with SCIG. A study done by
Chapel et al. had also reported higher trough level
in patients on SCIG therapy compared to IVIG, but
doses differing as per infusion centers, differences
in route of administration with no statistical evalu-
ation of achieved serum IgG level make the com-
parison difﬁcult.4 Similar ﬁndings were reported
by Bonagura et al. as well.25 These ﬁndings may
be due to the fact that pharmacokinetics of IgG
tends to differ when smaller doses are given
more frequently as compared to large boluses
given on a monthly basis. SCIG therapy has been
noted to have lower peaks and higher IgG
troughs. A total IgG dose divided into three or
four equal portions in weekly intervals is
expected to have less variation and ﬂuctuations
of IgG trough level, approximately 900 mg/dl
difference in peak and trough level after IVIG
infusion in comparison to 100 mg/dl difference
of the same after SCIG infusion.26 Another study
by Radinski advocated that frequent SCIG dosing
allows better maintenance of consistent serum
IgG levels.27 Although our study favored higher
level of IgG trough on SCIG therapy, increment
in the level per dose increase did not have a
linear correlation, and a similar ﬁnding was
observed with IVIG therapy as well. This could
have resulted from the variation of timing in
measuring trough levels in different studies.
Although the measurement of IgG trough level
was done prior to infusion in most studies, some
did not mention the exact timing of level drawn.
Whether trough levels should be used as a guide
for treatment remains controversial. Data from
earlier studies have endorsed IgG trough level of
500 mg/dl as an appropriate initial minimum
target for infection prevention in PIDD.18
However, subsequent clinical evidence has
prompted recommendations for higher target
levels of >800 mg/dl19 and 650–1000 mg/dl20 in
recent clinical guidelines. Due to inconsistent
trough levels, preference for individualized
treatment plan based on symptoms and infection
prevention are considered.3 More studies are
required to ascertain pharmacokinetic
parameters such as maximal concentration in
serum (Cmax), the time necessary to reach
concentration after complete infusion (Tmax) and
volume of distribution.
Similarly, a clear positive association of higher
trough levels with lower infection rates was seen
with SCIG in our meta-regression. Infection inci-
dence rate with trough 800–900 mg/dl at 4.97 (CI
4.3–5.8) precipitously decreased to 1.85 (CI 0.14–
3.6) and with trough level of 1200 þ mg/dl which
was statistically signiﬁcant at p ¼ 0.03.This relation,
however, was not seen with IVIG therapy. Although
we included 24 studies in our systematic review,
we could only include 11 studies in our meta-
analysis owing to lack of patient-level data. An
earlier meta-analysis done by Orange et al. had
also noted a signiﬁcant reduction in pneumonia
incidence (incidence rate ratio - 0.726, CI 0.658–
0.801), with a 27% reduction in pneumonia inci-
dence for each 100 mg/dl increment in trough
IgG.13 While this study’s analysis was limited to
pneumonia incidence, authors did suggest the
advantages of higher trough levels beneﬁtting
overall infection prevention as well. Comparison
of overall or serious infections between IVIG vs.
SCIG was not signiﬁcantly different, however, a
clinically signiﬁcant difference cannot be ruled
out due to a low number of patients and wide
conﬁdence interval seen.
The primary strength of this study is that it in-
cludes a large group of studies to quantify the
relationship of infection rate and IgG trough levels
in PIDD patients, along with the relationship of
dose vs. trough level in IVIG as well as SCIG modes
of treatment. Our results may have been
confounded by a focused presentation on the ef-
ﬁcacy of SCIG product, as most study trials were
developed by pharmaceutical companies. Another
caveat could be an effect seen by several studies in
the past which noted serum IgG levels to rise
continuously for months when previously un-
treated or under-treated patients received SCIG
therapy.26,28 Although the study includes studies
done in several countries with large patient data,
most studies are cohort studies, which limits the
overall strength of evidence.
Our study did not show a signiﬁcant difference
in overall infections or serious infections with IVIG
vs. SCIG, but a clinically signiﬁcant difference
cannot be ruled out. Based on our observation,
weekly SCIG attained a higher trough level in
comparison to monthly IVIG. Higher SCIG troughs
were associated with lower infection rates, while
IVIG troughs demonstrated no relationship. More
Volume 12, No. 10, October 2019 13
randomized controlled trials are required to look
at the effect of dosing with serum IgG trough
levels, and more importantly its effect on infection
prevention.
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